- Home
- OBE vs AVXL Comparison
OBE vs AVXL Comparison
Compare OBE & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OBE
- AVXL
- Stock Information
- Founded
- OBE 1979
- AVXL 2004
- Country
- OBE Canada
- AVXL United States
- Employees
- OBE N/A
- AVXL N/A
- Industry
- OBE Oil & Gas Production
- AVXL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OBE Energy
- AVXL Health Care
- Exchange
- OBE Nasdaq
- AVXL Nasdaq
- Market Cap
- OBE 432.5M
- AVXL 484.2M
- IPO Year
- OBE N/A
- AVXL N/A
- Fundamental
- Price
- OBE $5.92
- AVXL $8.96
- Analyst Decision
- OBE Strong Buy
- AVXL Strong Buy
- Analyst Count
- OBE 1
- AVXL 2
- Target Price
- OBE $14.00
- AVXL $43.00
- AVG Volume (30 Days)
- OBE 389.9K
- AVXL 1.6M
- Earning Date
- OBE 10-31-2024
- AVXL 11-25-2024
- Dividend Yield
- OBE N/A
- AVXL N/A
- EPS Growth
- OBE N/A
- AVXL N/A
- EPS
- OBE 1.05
- AVXL N/A
- Revenue
- OBE $516,155,298.00
- AVXL N/A
- Revenue This Year
- OBE $28.71
- AVXL N/A
- Revenue Next Year
- OBE $12.85
- AVXL N/A
- P/E Ratio
- OBE $4.86
- AVXL N/A
- Revenue Growth
- OBE 3.06
- AVXL N/A
- 52 Week Low
- OBE $5.24
- AVXL $3.25
- 52 Week High
- OBE $9.07
- AVXL $10.45
- Technical
- Relative Strength Index (RSI)
- OBE 54.10
- AVXL 63.88
- Support Level
- OBE $5.46
- AVXL $7.18
- Resistance Level
- OBE $5.73
- AVXL $10.45
- Average True Range (ATR)
- OBE 0.22
- AVXL 0.81
- MACD
- OBE 0.02
- AVXL -0.01
- Stochastic Oscillator
- OBE 65.00
- AVXL 48.30
About OBE Obsidian Energy Ltd.
Obsidian Energy Ltd is an intermediate-sized oil and gas producer with strategic assets in Alberta. It operates in a single reporting segment that is exploration, development, and holding an interest in oil and natural gas properties and related production infrastructure in the Western Canada Sedimentary Basin. The company generates the majority of the revenue from the Crude oil sale.
About AVXL Anavex Life Sciences Corp.
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.